Pulmonary Medicine

Research Article

Do Causes Influence Functional Aspects and Quality of Life in Patients with Nonfibrocystic Bronchiectasis?

Table 3

Comparison of patients according to the degree of dyspnea: clinical, functional, and quality of life ().


Variables	Few symptoms (mMRC 0-1) ()	Very symptomatic () ()	value

Clinical data
Age (years)			0.088
Female gender, (%)	44 (49.4)	52 (66.7)	0.025
Male gender, (%)	45 (50.6)	26 (33.3)
BMI (kg/m²)			0.232
Symptoms, (%)
Cough	53 (79.1)	52 (85.2)	0.366
Dry cough	20 (29.9)	14 (23.0)	0.377
Productive cough	33 (49.3)	38 (63.3)	0.111
Wheezing	41 (61.2)	46 (75.4)	0.085
Smoking, (%)	26 (2.2)	35 (44.9)	0.036
Pack-years			0.062
Wood stove exposition, (%)	36 (44.4)	31 (45.6)	0.889
Hospitalization (last year), (%)	9 (11.0)	22 (30.1)	0.003
Exacerbation (last year), (%)	33 (40.2)	46 (65.8)	0.002
Comorbidities, (%)
Systemic arterial hypertension	36 (40.9)	36 (46.2)	0.496
Diabetes mellitus	19 (21.8)	15 (19.5)	0.71
Dyslipidemia	15 (17.0)	11 (14.3)	0.627
CCI			0.372
Medications, (%)
ICS	60 (72.3)	56 (73.7)	0.843
Systemic corticosteroid	4 (4.8)	7 (9.2)	0.276
LABA	22 (26.5)	21 (27.6)	0.873
SABA	4 (4.8)	15 (19.7)	0.004
LAMA	29 (34.9)	38 (50.0)	0.055
SAMA	2 (2.4)	7 (9.2)	0.088
Macrolide	25 (30.1)	33 (43.4)	0.082
Home oxygen therapy	5 (5.8)	19 (25.0)	0.001
Functional data
SpO₂			0.01
Spirometry
FVC (L)			<0.0001
FVC (% of predicted)			0.007
FEV₁ (L)			<0.01
FEV₁ (% of predicted)			0.011
FEV₁/FVC			0.055
6MWT
6MWD (m)			0.002
6MWD as % of predicted value according to different prediction equations
Enright and Sherrill [11]			0.286
Iwama et al. [12]			0.012
Soares and Pereira [13]			0.036
Desaturation	14 (29.2)	12 (33.3)	0.683
Quality of life data
Symptom			<0.0001
Activity			<0.0001
Psychosocial impact			<0.0001
Total			<0.0001

Values expressed as deviation or as measures of frequency, as appropriate. % of predicted value according to different prediction equations. SpO₂ at the end of the %, or 4-point drop of initial SpO₂. BMI: body mass index; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; SpO₂: peripheral oxygen saturation; mMRC: Medical Research Council; SAH: systemic arterial hypertension; CCI: Charlson’s comorbidity index; ICS: inhaled corticosteroid; LABA: long-acting beta agonist; SABA: short-acting beta agonist; LAMA: long-acting muscarinic antagonist; SAMA: short-acting muscarinic antagonist.